About our company

Neurophyxia was founded in 2008 and is headquartered in ’s-Hertogenbosch, the Netherlands. The company has developed a novel neuroprotectant from early preclinical phase upto current Phase II Clinical Trials, thanks to its dedicated academic team,  backed-up by strong business and investment partners.

Neurophyxia is developing 2-iminobiotin (2-IB) for the treatment of cerebral reperfusion injury following stroke, cardiac arrest and birth asphyxia. See for more information neuroprotection.